2024
TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing
Loeb S, Keith S, Cheng H, Leader A, Gross L, Nolasco T, Byrne N, Hartman R, Brown L, Pieczonka C, Gomella L, Kelly W, Lallas C, Handley N, Mille P, Mark J, Brown G, Chopra S, McClellan A, Wise D, Hollifield L, Giri V. TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing. JCO Precision Oncology 2024, 8: e2300552. PMID: 38452310, PMCID: PMC10939575, DOI: 10.1200/po.23.00552.Peer-Reviewed Original ResearchConceptsGermline genetic testingDecisional conflictGenetic counselingProstate cancerPatient-drivenShortage of genetic counselorsKnowledge of cancer geneticsHereditary cancer riskReduce decisional conflictDecisional Conflict ScalePrimary outcome dataMixed-effects regression modelsDiverse patient populationsGenetic servicesClinical trial eligibilityGenetic counselorsGenetics educationPatient experienceCancer riskGermline testingAnalytical data setsCancer geneticsGermline evaluationConflict ScaleGenetic testing
2022
Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing
Loeb S, Cheng H, Leader A, Gross L, Nolasco T, Byrne N, Wise D, Hollifield L, Brown L, Slater E, Pieczonka C, Gomella L, Kelly W, Trabulsi E, Handley N, Lallas C, Chandrasekar T, Mille P, Mann M, Mark J, Brown G, Chopra S, Wasserman J, Phillips J, Somers P, Giri V. Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing. Contemporary Clinical Trials 2022, 119: 106821. PMID: 35710085, DOI: 10.1016/j.cct.2022.106821.Peer-Reviewed Original ResearchMeSH KeywordsAccelerationGenetic CounselingGenetic TestingGerm CellsHumansMaleProstatic NeoplasmsTechnologyConceptsKey patient-reported outcomesGermline testingPatient-reported outcomesProstate cancerGenetic counselingCollaborative care strategiesProstate cancer careTwo-armed randomizedProstate Cancer FoundationEducation/counselingGermline evaluationGOV IDENTIFIERPrimary outcomeSecondary outcomesStudy armsTarget enrollmentAshkenazi Jewish ancestryCancer careFamily historyTumor featuresCancer FoundationCare strategiesDecisional conflictUS sitesPractice settingsGermline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing
Giri V, Hartman R, Pritzlaff M, Horton C, Keith S. Germline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing. JCO Precision Oncology 2022, 6: e2200234. PMID: 35666082, PMCID: PMC9200399, DOI: 10.1200/po.22.00234.Peer-Reviewed Original ResearchMeSH KeywordsBlack or African AmericanGenes, BRCA2Genetic TestingGerm CellsHumansMaleMiddle AgedProstatic NeoplasmsConceptsGermline testingAA menWhite menHereditary cancer assessmentStandard clinical testingCohort of menAfrican American menGermline evaluationMultivariable analysisClinical managementBorderline associationLP variantsVariant statusClinical testingGermline analysisPanel testingRate of variantsCare deliveryVariant spectrumGenetic testingCancer assessmentUncertain significanceDNA repair genesGenetic counselingAmerican menGuidelines on Germline Testing for Urologic Tumor Syndromes
Gomella P, Mark J, Giri V, Kelly W, Gomella L. Guidelines on Germline Testing for Urologic Tumor Syndromes. European Urology Focus 2022, 8: 670-673. PMID: 35803854, DOI: 10.1016/j.euf.2022.06.010.Peer-Reviewed Original ResearchConceptsGermline testingCurrent guidelinesTumor syndromeTreatment of patientsScreening of patientsAvailability of testingDifferent organ systemsGenitourinary cancersGenitourinary tractUrologic cancersTreatment decisionsPatientsOrgan systemsGene mutationsCancerGenetic mutationsSyndromeFamily membersTreatmentGuidelinesMutationsTestingUse of geneticsTractGermline testing and genetic counselling in prostate cancer
Russo J, Giri V. Germline testing and genetic counselling in prostate cancer. Nature Reviews Urology 2022, 19: 331-343. PMID: 35449224, PMCID: PMC9022414, DOI: 10.1038/s41585-022-00580-7.Peer-Reviewed Original ResearchConceptsProstate cancerCancer risk managementCancer riskGenetic testingHereditary cancer predisposition syndromesPre-test discussionUnique clinical featuresGermline pathogenic variantsPrecision medicineHealth care professionalsComplex management optionsAdditional cancer riskCancer predisposition syndromeHereditary cancer riskGenetic counsellingGermline testingMetastatic diseaseClinical featuresOptimal careMedical historyFamily historyPathogenic variantsPrecision therapyGene testingCancerWhen to use germline genetic testing in prostate cancer.
Giri V. When to use germline genetic testing in prostate cancer. Clinical Advances In Hematology And Oncology 2022, 20: 78-81. PMID: 35120087.Commentaries, Editorials and Letters
2020
Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer
Loeb S, Giri V. Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer. European Urology Oncology 2020, 4: 1-9. PMID: 33390340, DOI: 10.1016/j.euo.2020.11.011.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsGermline testingLocalized diseaseMetastatic PCaFamily historyGermline evaluationMetastatic diseaseCurrent guidelinesProstate cancerCancer riskPractice settingsGenetic testingDNA mismatch repair deficiencyManagement of menProstate cancer managementFamily cancer riskEarly-stage PCaMismatch repair deficiencyHereditary cancer riskPathologic featuresHistologic featuresMedical oncologyCancer screeningPCa managementPCa riskConsensus panelPractical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC.
Szymaniak BM, Facchini LA, Giri VN, Antonarakis ES, Beer TM, Carlo MI, Danila DC, Dhawan M, George D, Graff JN, Gupta S, Heath E, Higano CS, Liu G, Molina AM, Paller CJ, Patnaik A, Petrylak DP, Reichert Z, Rettig MB, Ryan CJ, Taplin ME, Vinson J, Whang YE, Morgans AK, Cheng HH, McKay RR. Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. JCO Oncology Practice 2020, 16: 811-819. PMID: 32986533, PMCID: PMC7735040, DOI: 10.1200/op.20.00431.Peer-Reviewed Original ResearchMeSH KeywordsGenetic TestingGerm CellsGerm-Line MutationHumansMalePrecision MedicineProstatic NeoplasmsConceptsGermline genetic testingProstate cancerGenetic testingNumber of patientsCritical unmet needCurrent guidelinesTesting deliveryPatientsUnmet needPrecision oncologyGenomic testingGenetic counselingGenetics providersGenetic servicesClinical workflowCancerOncologyLimited accessWorking GroupGuidelinesStandardized systemProvidersTestingClinic
2018
Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing
Giri V, Hegarty S, Hyatt C, O'Leary E, Garcia J, Knudsen K, Kelly W, Gomella L. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing. The Prostate 2018, 79: 333-339. PMID: 30450585, DOI: 10.1002/pros.23739.Peer-Reviewed Original ResearchConceptsBreast cancer family historyCancer family historyProstate cancerFamily historyMetastatic diseaseGleason scoreExact testGenetic testingRetrospective cross-sectional analysisDNA repair genesCurrent NCCN guidelinesInherited prostate cancerGermline genetic testingHigh Gleason scoreFisher's exact testIdentification of menRepair genesPathogenic variant spectrumCross-sectional analysisFamily history dataGenetic testing capabilitiesNCCN guidelinesTherapeutic managementMultigene testingPV rates